Alentis Therapeutics raises 12.5 mln swiss francs
Alentis Therapeutics said April 30 that it completed a Series A financing round of 12.5 million swiss francs led by BioMedPartners and BB Pureos Bioventures. BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF) also participated in the round. Alentis is a Swiss-French biotech company developing therapeutics in advanced liver disease and cancer.
30 April 2019•3 mins read
